摘要 |
The present application addresses these and other needs by providing methods of treatment for the treatment of prostate cancer. In one aspect, the invention provides a method of reducing the expression of androgen receptor protein in a cell by contacting the cell with a 17-heteroarylsteroid compound. In some embodiments, the compound is Compound 1. In some embodiments, the level of androgen receptor protein is reduced following the step of contacting the cell with the 17-heteroarylsteroid compound. For example, the level of androgen receptor mRNA is reduced. In some embodiments, the cell is a LNCaP or LAPC4 cell. |
申请人 |
TOKAI PHARMACEUTICALS, INC.;STEIN, CY A.;SOIFER, HARRIS;CINAR, BEKIR;CHAPPEL, SCOTT |
发明人 |
STEIN, CY A.;SOIFER, HARRIS;CINAR, BEKIR;CHAPPEL, SCOTT |